MCID: 48X005
MIFTS: 39

48,xyyy

Categories: Fetal diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for 48,xyyy

Summaries for 48,xyyy

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 99329 Definition A rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability , large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males. Visit the Orphanet disease page for more resources.

MalaCards based summary : 48,xyyy, also known as 48,xyyy syndrome, is related to radioulnar synostosis, nonsyndromic and hypogonadotropic hypogonadism. The drugs Bazedoxifene and Nalbuphine have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and lung, and related phenotypes are global developmental delay and depressed nasal bridge

Related Diseases for 48,xyyy

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 radioulnar synostosis, nonsyndromic 10.2
2 hypogonadotropic hypogonadism 10.2

Symptoms & Phenotypes for 48,xyyy

Human phenotypes related to 48,xyyy:

58 31 (show all 31)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 global developmental delay 58 31 hallmark (90%) Very frequent (99-80%) HP:0001263
2 depressed nasal bridge 58 31 hallmark (90%) Very frequent (99-80%) HP:0005280
3 hypertelorism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000316
4 short neck 58 31 hallmark (90%) Very frequent (99-80%) HP:0000470
5 delayed speech and language development 58 31 hallmark (90%) Very frequent (99-80%) HP:0000750
6 pes planus 58 31 hallmark (90%) Very frequent (99-80%) HP:0001763
7 intellectual disability, mild 58 31 hallmark (90%) Very frequent (99-80%) HP:0001256
8 feeding difficulties 58 31 hallmark (90%) Very frequent (99-80%) HP:0011968
9 thick lower lip vermilion 58 31 hallmark (90%) Very frequent (99-80%) HP:0000179
10 recurrent upper respiratory tract infections 58 31 hallmark (90%) Very frequent (99-80%) HP:0002788
11 acne 58 31 hallmark (90%) Very frequent (99-80%) HP:0001061
12 high palate 58 31 hallmark (90%) Very frequent (99-80%) HP:0000218
13 abnormal dermatoglyphics 58 31 hallmark (90%) Very frequent (99-80%) HP:0007477
14 epicanthus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000286
15 azoospermia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000027
16 long philtrum 58 31 hallmark (90%) Very frequent (99-80%) HP:0000343
17 asthma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002099
18 radioulnar synostosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002974
19 tall stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0000098
20 dislocated radial head 58 31 hallmark (90%) Very frequent (99-80%) HP:0003083
21 aggressive behavior 58 31 hallmark (90%) Very frequent (99-80%) HP:0000718
22 abnormal renal morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0012210
23 low frustration tolerance 58 31 hallmark (90%) Very frequent (99-80%) HP:0000744
24 male hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000026
25 impulsivity 58 31 hallmark (90%) Very frequent (99-80%) HP:0100710
26 primary gonadal insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0008193
27 hypoplasia of dental enamel 58 31 hallmark (90%) Very frequent (99-80%) HP:0006297
28 irregularly spaced teeth 58 31 hallmark (90%) Very frequent (99-80%) HP:0006316
29 intellectual disability 58 Very frequent (99-80%)
30 behavioral abnormality 58 Very frequent (99-80%)
31 abnormality of the foot 58 Very frequent (99-80%)

Drugs & Therapeutics for 48,xyyy

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1608)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
2
Nalbuphine Approved Phase 4 20594-83-6 5311304 5360630
3
Amantadine Approved Phase 4 768-94-5 2130
4
Propafenone Approved Phase 4 54063-53-5 4932
5
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
6
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
7
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
8
Riociguat Approved Phase 4 625115-55-1
9
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
10
Lincomycin Approved, Vet_approved Phase 4 154-21-2 656509
11
Fenoldopam Approved Phase 4 67227-57-0, 67227-56-9 3341
12
Eleuthero Approved, Experimental Phase 4
13
Hexetidine Approved, Investigational Phase 4 141-94-6
14
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
15
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
16
Cobicistat Approved Phase 4 1004316-88-4
17
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
18
Donepezil Approved Phase 4 120014-06-4 3152
19
Nifedipine Approved Phase 4 21829-25-4 4485
20
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
21
Zidovudine Approved Phase 4 30516-87-1 35370
22
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
23
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
24
Saw palmetto Approved, Experimental, Investigational Phase 4
25
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
26
Eplerenone Approved Phase 4 107724-20-9 150310 443872
27
carbamide peroxide Approved Phase 4 124-43-6
28
Metformin Approved Phase 4 657-24-9 14219 4091
29
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
30
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
31
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
32
Pamidronate Approved Phase 4 40391-99-9 4674
33
Omalizumab Approved, Investigational Phase 4 242138-07-4
34
Mycophenolic acid Approved Phase 4 24280-93-1 446541
35
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
36
Norepinephrine Approved Phase 4 51-41-2 439260
37
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
38
Natalizumab Approved, Investigational Phase 4 189261-10-7
39
Orphenadrine Approved Phase 4 83-98-7 4601
40
Indinavir Approved Phase 4 150378-17-9 5362440
41
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
42
Dezocine Approved, Investigational Phase 4 53648-55-8 40841 3033053
43
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
44
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
45
Tavaborole Approved, Investigational Phase 4 174671-46-6
46
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
47
Fosamprenavir Approved Phase 4 226700-79-4 131536
48
Nefopam Approved, Investigational Phase 4 13669-70-0
49
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
50
Atenolol Approved Phase 4 29122-68-7 2249

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
2 Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks Unknown status NCT02470650 Phase 4 elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
3 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
4 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
5 Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients Unknown status NCT02602704 Phase 4 Bazedoxifene;Calcium/Vit D
6 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
7 Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy Unknown status NCT01893788 Phase 4 Aliskiren;Eplerenone
8 The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital: A Randomized Clinical Trial Unknown status NCT01339065 Phase 4 Ketamine
9 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
10 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
11 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
12 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
13 Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a Unknown status NCT02368288 Phase 4 entecavir
14 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
15 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
16 Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine Unknown status NCT01256866 Phase 4 Dexmedetomidine;Midazolam
17 Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery. Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
18 Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification Unknown status NCT01546974 Phase 4
19 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone. Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
20 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
21 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
22 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
23 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
24 A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
25 A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides Unknown status NCT02644538 Phase 4 PegIFN alfa-2a
26 Post Operative Pain Control Among Intrathecal 0.1 mg Morphine, Femoral Nerve Block, or Periarticular Infiltration of 20 mL of 0.25% Bupivacaine in Patients Post Intramedullary Hip Screw Unknown status NCT01219088 Phase 4 Bupivacaine, morphine
27 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
28 Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit. Unknown status NCT01883596 Phase 4 0.12% chlorhexidine solution;Placebo
29 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
30 Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
31 An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine Unknown status NCT00199121 Phase 4 Zidovudine (drug)
32 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
33 Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA) Unknown status NCT01698203 Phase 4 ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun);Placebo;ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)
34 Comparison of the Efficacy and Safety of NALDEBAIN With Conventional Treatment After Laparoscopic Cholecystectomy Unknown status NCT03713216 Phase 4 Naldebain;Morphine
35 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
36 Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial> Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
37 Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity Unknown status NCT02770794 Phase 4 Infliximab
38 Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial Unknown status NCT00615875 Phase 4 naproxen;placebo
39 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
40 Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
41 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
42 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
43 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
44 Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Unknown status NCT02577159 Phase 4 Dapagliflozin
45 Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595 Unknown status NCT02367599 Phase 4 Vitamin D Supplement
46 Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically Unknown status NCT02355093 Phase 4 ropivacaine
47 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
48 Antibiotic Prophylaxis in Prosthetic Breast Reconstructions Unknown status NCT02012517 Phase 4 Prolonged antibiotic treatment;Short antibiotic course (standard of care)
49 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
50 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir

Search NIH Clinical Center for 48,xyyy

Genetic Tests for 48,xyyy

Anatomical Context for 48,xyyy

MalaCards organs/tissues related to 48,xyyy:

40
Testes, Liver, Lung, Brain, Breast, Kidney, Heart

Publications for 48,xyyy

Articles related to 48,xyyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Diosgenin and 4-Hydroxyisoleucine from Fenugreek Are Regulators of Genes Involved in Lipid Metabolism in The Human Colorectal Cancer Cell Line SW480. 61
32347045 2021
2
The enhanced removal of phosphate by structural defects and competitive fluoride adsorption on cerium-based adsorbent. 61
32447108 2020
3
Antibacterial Properties and Application of Nanosilver Material in the Tracheal Tube. 61
32385011 2020
4
Ambient fine particulate matter pollution and years of life lost from cardiovascular diseases in 48 large Chinese cities: Association, effect modification, and additional life gain. 61
32480149 2020
5
GPR17 plays a role in ischemia-induced endogenous repair of immature neonatal cerebral White matter. 61
32387084 2020
6
Modulation of chloroplast components and defense responses during programmed cell death in tobacco infected with Pseudomonas syringae. 61
32527587 2020
7
Positive effect of natural antioxidant oregonin from Alnus incana bark on ram semen quality stored at 5 °C for 48 h. 61
32387554 2020
8
Insight into the role of integrated carbohydrate polymers (starch, chitosan, and β-cyclodextrin) with mesoporous silica as carriers for ibuprofen drug; equilibrium and pharmacokinetic properties. 61
32294500 2020
9
Testicular hyperthermia reduces testosterone concentrations and alters gene expression in testes of Nelore bulls. 61
32380276 2020
10
Assessing the acute and chronic toxicity of exposure to naturally occurring oil sands deposits to aquatic organisms using Daphnia magna. 61
32380325 2020
11
The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis. 61
32170983 2020
12
Prediction of the need for phototherapy during hospital stay in preterm infants by transcutaneous bilirubinometry. 61
32442814 2020
13
Diagnostic value of bronchoalveolar lavage and bronchial washing in sputum-scarce or smear-negative cases with suspected pulmonary tuberculosis: a randomized study. 61
31759097 2020
14
Incidence of postoperative pain after canal shaping by using Reciproc and Twisted File Adaptive systems: a prospective, randomized clinical trial. 61
31673858 2020
15
Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. 61
32134108 2020
16
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial). 61
32259255 2020
17
Motility and Fertility Evaluation of Thawed Frozen Stallion Semen After 24 Hours of Cooled Storage. 61
32534766 2020
18
Betahistine in the Treatment of Peripheral Vestibular Vertigo: Results of a Real-Life Study in Primary Care. 61
31111729 2020
19
Evidence that activin A directly modulates early human male germline differentiation status. 61
32484162 2020
20
Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. 61
32387968 2020
21
Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China. 61
32364959 2020
22
18F-FDG PET/CT in Follicular Dendritic Cell Sarcoma With Paraneoplastic Pemphigus as the First Manifestation. 61
32371617 2020
23
Ketoprofen affects swimming behavior and impairs physiological endpoints of Daphnia magna. 61
32304961 2020
24
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study. 61
32101882 2020
25
Virulence, antimicrobial resistance and phylogenetic analysis of zoonotic walking pneumonia Mycoplasma arginini in the one-humped camel (Camelus dromedarius). 61
32330451 2020
26
Safety and effectiveness of medication and aspiration abortion before or during the sixth week of pregnancy: A retrospective multicenter study. 61
32298713 2020
27
DAMGO-induced μ opioid receptor internalization and recycling restore morphine sensitivity in tolerant rat. 61
32320702 2020
28
Assessment of cyto- and genotoxic effects of Cesium-133 in Vicia faba using single-cell gel electrophoresis and random amplified polymorphic DNA assays. 61
32311615 2020
29
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. 61
32304611 2020
30
Correction to: Transcriptional and metabolite analysis reveal a shift in direct and indirect defences in response to spider‑mite infestation in cucumber (Cucumis sativus). 61
32350663 2020
31
Effect of self-performed mechanical plaque control frequency on gingival health in subjects with a history of periodontitis: A Randomized Clinical Trial. 61
32315448 2020
32
How successful are we in relieving terminal dyspnea in cancer patients? A real-world multicenter prospective observational study. 61
31630256 2020
33
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. 61
31687762 2020
34
Transporting and Exercising Unconditioned Horses: Effects on Microflora Populations. 61
32534767 2020
35
Intravenous Ibuprofen Reduces Opioid Consumption During the Initial 48 Hours After Injury in Orthopedic Trauma Patients. 61
31929374 2020
36
OXA-48 carbapenemase-producing Salmonella enterica serovar Kentucky ST198 isolated from Saudi Arabia. 61
32154842 2020
37
Carbapenem Resistance Conferred by OXA-48 in K2-ST86 Hypervirulent Klebsiella pneumoniae, France. 61
32568057 2020
38
Assessment of the Urinary Microbiome in Children Younger Than 48 Months. 61
32091499 2020
39
DEX-2-TKA - DEXamethasone twice for pain treatment after Total Knee Arthroplasty: Detailed statistical analysis plan for a randomized, blinded, three-group multicentre clinical trial. 61
32048274 2020
40
An examination of changes in skeletal muscle thickness, echo intensity, strength and soreness following resistance exercise. 61
32187417 2020
41
Risk Factors of Nonunion After Acute Osteoporotic Vertebral Fractures: A Prospective Multicenter Cohort Study. 61
32044808 2020
42
Clinical and pathological features and varied mutational spectra of pathogenic genes in 55 Chinese patients with nephronophthisis. 61
32173348 2020
43
Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design. 61
32485328 2020
44
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. 61
32381562 2020
45
Early postnatal changes of circulating N-terminal-pro-B-type natriuretic peptide in neonates with congenital diaphragmatic hernia. 61
32402829 2020
46
In vitro evaluation of physicochemical properties of soft lining resins after incorporation of chlorhexidine. 61
32540125 2020
47
Assessing the effectiveness of AS-48 in experimental mice models of Chagas' disease. 61
32129856 2020
48
Quantitative and Qualitative Assessments of Cholesterol Association With Bacterial Infection Type in Sepsis and Septic Shock. 61
32578468 2020
49
Treatment of a tuberculous esophagomediastinal fistula with a covered metal stent. 61
32579016 2020
50
Evaluation of Prognostic Factors of Severity in Acute Biliary Pancreatitis. 61
32560276 2020

Variations for 48,xyyy

Expression for 48,xyyy

Search GEO for disease gene expression data for 48,xyyy.

Pathways for 48,xyyy

GO Terms for 48,xyyy

Sources for 48,xyyy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....